Bioluminescent Study of the Distribution of High-Molecular-Weight Protein Fraction of Cellex Daily Preparation in the Brain after Intranasal Administation


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Permeability of the blood—brain barrier for protein fractions 50-100 kDa (PF50–100) of Cellex Daily preparation labeled with fluorescent tracer FITC and non-conjugated FITC were compared after intranasal administration of the preparations to healthy rats. Fluorimetrical analysis of the serum and cerebrospinal fluid samples showed that Cellex Daily PF50–100-FITC administered intranasally penetrated into the blood and cerebrospinal fluid with maximum accumulation in 2 h after administration and persists in the circulation for 24 h probably due to binding with plasma proteins. The differences in the kinetic profile of PF50–100-FITC and free FITC indirectly suggest that the major part of the preparation is not degraded within 24 h and FITC is probably not cleaved from the protein components of the preparation. In vivo fluorescence analysis showed significant fluorescent signal in the olfactory bulbs in 6 h after intranasal administration; hence, the preparation administered via this route can bypass the blood—brain barrier. Scanning laser confocal microscopy of rat brain sections confirmed penetration of the high-molecular weight protein fraction PF50–100-FITC into CNS structures. The most pronounced accumulation of the labeled drug was observed in the olfactory bulb in 6 and 12 h after administration. In contrast to free FITC administered in the control group, significant accumulation of PF50–100-FITC in the olfactory cortex and frontal cortex neurons with functionally active nuclei was observed in 6, 12 and 24 h after intranasal administration.

Авторлар туралы

V. Baklaushev

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency

Хат алмасуға жауапты Автор.
Email: serpoff@gmail.com
Ресей, Moscow

G. Yusubalieva

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Ресей, Moscow

M. Burenkov

Farm-Sintez Company

Email: serpoff@gmail.com
Ресей, Moscow

P. Mel’nikov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency; V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Ресей, Moscow; Moscow

E. Bozhko

Farm-Sintez Company

Email: serpoff@gmail.com
Ресей, Moscow

G. Mentyukov

Farm-Sintez Company

Email: serpoff@gmail.com
Ресей, Moscow

L. Lavrent’eva

Farm-Sintez Company

Email: serpoff@gmail.com
Ресей, Moscow

M. Sokolov

Farm-Sintez Company

Email: serpoff@gmail.com
Ресей, Moscow

V. Chekhonin

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Ресей, Moscow; Moscow


© Springer Science+Business Media, LLC, part of Springer Nature, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>